UK Privacy Watchdog Launches Probe Into Bedroom Camera Surveillance of Mental Health Patients

UK Privacy Watchdog Investigates Bedroom Surveillance Technology in Mental Health Wards

Britain's information commissioner has formally launched an investigation into a contentious bedroom monitoring system deployed across 40% of NHS mental health trusts, following growing concerns over data privacy, patient consent, and the system's potential impact on vulnerable individuals.

The system in question, known as Oxevision and developed by a company now rebranded as LIO (formerly Oxehealth), uses infrared sensors and cameras to remotely monitor patients around the clock. While the company maintains that the technology improves patient safety and reduces pressure on NHS staff, critics — including bereaved families, patient advocates, and legal experts — argue it is intrusive, potentially unlawful, and may cause more harm than good.

Legal Challenge Triggers Official Investigation

The Information Commissioner's Office (ICO) confirmed it had opened a formal inquiry into Oxehealth after lawyers from Bindmans, representing the campaign group Stop Oxevision, formally requested scrutiny of how the system collects, stores, and processes sensitive patient data, including video footage captured inside hospital bedrooms.

Rachel Harger, a partner at Bindmans, emphasised the importance of privacy in clinical settings: "A patient's bedroom in hospital should, as far as possible, remain a sanctuary for care and treatment, where privacy is respected. Organisations must be able to point to a clear lawful basis for this collection and processing of patient-derived data. Where they rely on consent, it must be properly obtained, freely given, and capable of being withdrawn."

The ICO declined to provide further comment beyond confirming the investigation was underway.

Tragedy Puts Spotlight on the Technology

The investigation comes amid heightened scrutiny of the technology through the ongoing Lampard inquiry, which is examining thousands of deaths involving mental health patients in Essex.

One of those cases involves Sophie Alderman, a 27-year-old woman with a history of serious mental illness and self-harm, who died by suicide in August 2022 at Rochford Hospital in Essex while being monitored by the Oxevision system. Her mother, Tammy Smith, has spoken out powerfully about the system's failings and its effect on her daughter's mental state.

Giving evidence to the inquiry in October, Smith said: "I think her paranoia would have been increased 100%. She's always been uncomfortable with cameras. She always felt under a microscope… it was obvious that Sophie was distressed by the presence of the camera in her room but, worst of all, the system did not even keep her safe."

She added a stark warning about the limits of technology in mental health care: "You cannot replace staff in that situation with technology. It's not fit for purpose."

Patients Describe Surveillance as 'Creepy' and Invasive

Beyond individual cases, patients more broadly have described the experience of being monitored by Oxevision as unsettling and dehumanising, with some characterising it as a form of spying. The system films patients continuously throughout the day and night inside their bedrooms — a reality that Laura Cozens, head of patient safety at LIO, acknowledged constitutes "a very significant invasion of privacy" when she addressed the Lampard inquiry.

Cozens did note that video recordings are accessible only upon formal request and are subject to strict governance protocols. She also conceded that the technology may not be appropriate for all patients.

Campaigners and Legal Experts Call for Urgent Action

Selen Cavcav from the charity Inquest, who served as a caseworker for Sophie Alderman's family, argued that surveillance-based approaches are fundamentally at odds with good mental health care.

"People in mental health settings need care — not isolation and surveillance," she said. "The use of intrusive technologies like Oxevision can exacerbate emotional distress and existing issues in mental health settings, such as the coercive nature of treatment and the lack of privacy. Instead of systems which allow private companies to put profit over people, we need to imagine and resource genuine alternatives which centre people's dignity and autonomy."

Nina Ali, a solicitor at Hodge Jones & Allen representing over 150 families at the Lampard inquiry, raised concerns that the technology may actually be contributing to preventable deaths by encouraging staff to rely on automated alerts rather than conducting face-to-face observations.

"As things stand, the use of Oxevision in Essex is unsafe, intrusive and potentially unlawful, and urgent recommendations are needed to protect patients," Ali said. "We have seen multiple cases where staff relied on assistive technology instead of carrying out proper in-person observations, including in cases where deaths occurred as system alerts were muted, ignored or misunderstood. There is no place for any kind of surveillance of that sort for patients with mental health issues in their bedrooms."

Company Defends the Technology's Role in Saving Lives

Oxehealth has pushed back firmly against what it describes as a misleading narrative around its product. In a statement, a spokesperson said the company is engaging constructively with the ICO and rejected the idea that unmonitored bedrooms are inherently safer environments for acutely unwell psychiatric patients.

The company pointed to clinical data submitted to the Lampard inquiry, stating that on Essex Partnership University NHS Trust (EPUT) wards alone, the platform had flagged 935 ligature incidents and 436 self-harm events, enabling staff to intervene in time-critical situations.

The spokesperson also cited EPUT representatives who told the inquiry: "The use of Oxevision has assisted EPUT to make more timely interventions when required and therefore assisted in preserving life."

What Happens Next

The Lampard inquiry is scheduled to hear further evidence next month specifically relating to the use of Oxevision on EPUT mental health wards. Stop Oxevision welcomed the ICO's decision to investigate, calling independent scrutiny "both necessary and overdue" and urging that the probe be treated as a matter of urgent priority for all those affected.

The outcome of the investigation could have significant implications for how the NHS deploys monitoring technology in sensitive clinical environments and what safeguards must be in place to protect patient rights.

---

If you or someone you know is struggling, support is available. In the UK and Ireland, contact Samaritans on freephone 116 123. In the US, call or text 988 to reach the National Suicide Prevention Lifeline. In Australia, Lifeline can be reached on 13 11 14. International resources are available at befrienders.org.